tradingkey.logo

Veracyte Inc

VCYT

23.955USD

+0.315+1.33%
Horarios del mercado ETCotizaciones retrasadas 15 min
1.88BCap. mercado
56.76P/E TTM

Veracyte Inc

23.955

+0.315+1.33%
Más Datos de Veracyte Inc Compañía
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Información de la empresa
Símbolo de cotizaciónVCYT
Nombre de la empresaVeracyte Inc
Fecha de salida a bolsaOct 30, 2013
Director ejecutivoMr. Marc A. Stapley
Número de empleados824
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 30
Dirección6000 Shoreline Court, Suite 300
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94080
Teléfono16502436300
Sitio Webhttps://www.veracyte.com/
Símbolo de cotizaciónVCYT
Fecha de salida a bolsaOct 30, 2013
Director ejecutivoMr. Marc A. Stapley
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
116.51K
-7.46%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
62.45K
+17.55%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
33.34K
-13.87%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
32.81K
+39.68%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
32.19K
+40.76%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
27.84K
+20.48%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
25.73K
+56.82%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
13.09K
-18.41%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Director
Independent Director
11.76K
+67.35%
Ms. Annie Mcguire
Ms. Annie Mcguire
Chief Human Resources Officer, General Counsel
Chief Human Resources Officer, General Counsel
10.19K
-25.60%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
116.51K
-7.46%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
62.45K
+17.55%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
33.34K
-13.87%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
32.81K
+39.68%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
32.19K
+40.76%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
27.84K
+20.48%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2024
FY2023
FY2022
FY2021
FY2020
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
423.54M
95.01%
International
22.23M
4.99%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.53%
BlackRock Institutional Trust Company, N.A.
7.92%
Fidelity Management & Research Company LLC
7.88%
Artisan Partners Limited Partnership
6.69%
Wellington Management Company, LLP
4.92%
Other
62.06%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.53%
BlackRock Institutional Trust Company, N.A.
7.92%
Fidelity Management & Research Company LLC
7.88%
Artisan Partners Limited Partnership
6.69%
Wellington Management Company, LLP
4.92%
Other
62.06%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
59.74%
Investment Advisor/Hedge Fund
38.69%
Hedge Fund
4.35%
Research Firm
1.79%
Pension Fund
1.28%
Venture Capital
0.97%
Individual Investor
0.59%
Bank and Trust
0.44%
Sovereign Wealth Fund
0.29%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
597
84.71M
108.17%
-889.52K
2025Q1
612
85.86M
109.67%
-679.43K
2024Q4
593
81.64M
104.75%
-2.62M
2024Q3
567
81.88M
106.62%
-2.30M
2024Q2
533
81.65M
106.83%
-3.86M
2024Q1
532
81.30M
103.75%
+1.22M
2023Q4
524
76.49M
104.40%
-3.87M
2023Q3
520
77.05M
105.90%
-3.78M
2023Q2
516
77.28M
106.70%
-4.52M
2023Q1
533
77.62M
107.25%
-6.79M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
8.25M
10.53%
+52.03K
+0.64%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.21M
7.92%
-41.84K
-0.67%
Mar 31, 2025
Fidelity Management & Research Company LLC
6.17M
7.88%
+4.15M
+205.06%
Mar 31, 2025
Artisan Partners Limited Partnership
5.24M
6.69%
-1.36M
-20.60%
Mar 31, 2025
Wellington Management Company, LLP
3.85M
4.92%
-231.44K
-5.67%
Mar 31, 2025
ARK Investment Management LLC
3.21M
4.09%
-286.15K
-8.20%
May 31, 2025
ArrowMark Colorado Holdings, LLC
3.23M
4.12%
+146.65K
+4.76%
Mar 31, 2025
State Street Global Advisors (US)
3.16M
4.03%
+247.55K
+8.50%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.91M
3.72%
+28.17K
+0.98%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.93M
2.47%
+94.91K
+5.16%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ARK Genomic Revolution ETF
3.09%
First Trust NYSE Arca Biotechnology Index Fund
2.67%
Global X Genomics & Biotechnology ETF
2.67%
Invesco Biotechnology & Genome ETF
2.57%
WisdomTree BioRevolution Fund
1.69%
ROBO Global Healthcare Technology & Innovation ETF
1.42%
ROBO Global Artificial Intelligence ETF
1.24%
ARK Innovation ETF
0.98%
Franklin Genomic Advancements ETF
0.88%
SPDR S&P Biotech ETF
0.74%
Ver más
ARK Genomic Revolution ETF
Proporción3.09%
First Trust NYSE Arca Biotechnology Index Fund
Proporción2.67%
Global X Genomics & Biotechnology ETF
Proporción2.67%
Invesco Biotechnology & Genome ETF
Proporción2.57%
WisdomTree BioRevolution Fund
Proporción1.69%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.42%
ROBO Global Artificial Intelligence ETF
Proporción1.24%
ARK Innovation ETF
Proporción0.98%
Franklin Genomic Advancements ETF
Proporción0.88%
SPDR S&P Biotech ETF
Proporción0.74%
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI